Welcome to our dedicated page for Iridex news (Ticker: IRIX), a resource for investors and traders seeking the latest updates and insights on Iridex stock.
Iridex Corporation develops, manufactures, and markets laser-based medical systems, delivery devices, procedure probes, accessories, and consumable instrumentation for ophthalmology. Its products support treatment of glaucoma, diabetic macular edema, and other retinal diseases, with proprietary MicroPulse® technology used across parts of its portfolio.
Iridex news commonly covers quarterly and annual financial results, business updates, product-family activity for systems such as Cyclo G6®, retina laser platforms including PASCAL®, IQ 532®, IQ 577®, and OcuLight® TX, and clinical literature involving MicroPulse transscleral laser therapy. Company updates also address commercial partnerships, U.S. direct sales, international distributor activity, operational efficiency measures, and Nasdaq listing-status matters.
Iridex (Nasdaq: IRIX) will present at the Planet MicroCap Las Vegas 2026 Conference. Management is scheduled to present on Wednesday, June 17, 2026 at 4:00 pm PT.
A live and archived webcast will be available via the Event Calendar in the Investors section of the company website.
Iridex (Nasdaq: IRIX) reported Q1 2026 revenue of $11.8 million, down 1% year-over-year. Cyclo G6 product revenue rose 14% to $3.6 million, while retina revenue declined to $5.8 million. Gross margin was 40%, operating expenses fell 4% to $5.1 million, and net loss narrowed to $0.5 million ($0.03 per share).
Non-GAAP adjusted EBITDA was $0.3 million. Cash was $4.6 million, down $1.4 million, with usage concentrated in Q1. Iridex reaffirmed 2026 revenue guidance of $51–$53 million, expects 2026 adjusted operating expenses of $19–$19.5 million, and projects positive operating cash flow for fiscal 2026.
Iridex (Nasdaq: IRIX) will release first-quarter 2026 financial results and provide a business update after market close on May 19, 2026. Management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET with live and recorded webcast access via the company website.
Investors can join by phone using Conference ID 9329659 or listen on the Events page at www.iridex.com.
Iridex (Nasdaq: IRIX) announced a partnership with EyeProGPO on April 7, 2026 to provide preferred pricing and expanded access to Iridex retina lasers for more than 1,800 EyeProGPO members.
The agreement adds PASCAL®, IQ 532®, IQ 577®, and OcuLight® TX to EyeProGPO offerings and builds on existing Cyclo G6® and glaucoma probe contracts, aiming to streamline purchasing and broaden clinical access for ophthalmology practices, ASCs, and hospitals.
Iridex (Nasdaq: IRIX) reported Q4 and full-year 2025 results with revenue momentum and cost reductions. Q4 revenue was $14.7M (+16% YoY) and full-year revenue was $52.7M (+8% YoY). Operating expenses declined 22% for FY2025 and adjusted EBITDA turned positive at $1.1M.
The company forecasts 2026 revenue of $51M–$53M and expects positive operating cash flow, while noting Middle East disruptions affecting deliveries.
Iridex (Nasdaq: IRIX) will report fourth quarter and full year 2025 financial results on March 26, 2026 after market close and provide a business update.
Management will host a conference call on March 26, 2026 at 2:00 p.m. PT / 5:00 p.m. ET with live and recorded webcast access on the company website.
Iridex (Nasdaq: IRIX) announced plans to relocate its headquarters from Mountain View, CA to San Jose, CA, under a non-binding letter of intent dated Jan 26, 2026. The company expects to occupy a 31,000 square foot location and forecasted savings of $0.4 million in fiscal 2026 and $0.6 million annualized.
The Lease terms remain subject to change and may not be executed as currently described; the company said the move aims to lower operating expenses while maintaining reduced manufacturing operations and Bay Area talent.
Iridex (NASDAQ: IRIX) reported preliminary unaudited results for the quarter and year ended Jan 3, 2026. Q4 2025 revenue is expected to be $14.6M–$14.8M, up 15%–17% year‑over‑year. The company achieved positive cash flow in Q4 and sold 15,800 Cyclo G6 probes (vs. 13,300 prior year). Full‑year 2025 revenue is expected to be $52.5M–$52.7M (about 8% growth). Iridex expects to achieve positive adjusted EBITDA for 2025. Results remain preliminary and subject to final close and audit.
Iridex (Nasdaq: IRIX) announced publication of an independent retrospective study in Ophthalmology and Therapy showing that retreatment with MicroPulse TLT safely and effectively lowers intraocular pressure (IOP) in glaucoma patients.
The study of 76 eyes at University Eye Clinic Maastricht found meaningful IOP reductions ~25%–35% at three months after retreatment across patient groups. Retreatment timing varied from about 4 months to > 28 months, with second-retreatment intervals of ~3 months to 2 years, supporting repeatability and flexible use in real-world practice.
Iridex (Nasdaq: IRIX) announced a newly published computational study in Translational Vision Science & Technology modeling thermal dynamics of transscleral glaucoma lasers.
The Monte Carlo simulations compared continuous-wave TSCPC (CW-TSCPC) and MicroPulse TLT using Iridex Cyclo G6, G-Probe and MicroPulse P3. Results: CW-TSCPC produced a ~2 mm thermal zone with temperatures >100°C for ~2.2 seconds, while MicroPulse TLT produced a smaller 0.6–1.2 mm zone with peak temperatures below 100°C and more uniform heat distribution.
Authors say both techniques lie on a thermal continuum and may serve complementary clinical roles with further optimization.